Evidence map›Paper›PMID 36419080›Full record

ArticleCancer cell international2022

Spatial metabolomics on liver cirrhosis to hepatocellular carcinoma progression.

Michelle Junyi He, Wenjun Pu, Xi Wang, Xiaoni Zhong, Dong Zhao, Zhipeng Zeng, Wanxia Cai, Jiayi Liu, Jianrong Huang, Donge Tang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Subtype specific immune-metabolic reprogramming in preeclampsia revealed by multiomics and serum biomarkers.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Michelle Junyi He *Clinical Medical Research Center, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, No. 1017 Dongmen North Road, Shenzhen, 518020, China.
Wenjun Pu *Clinical Medical Research Center, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, No. 1017 Dongmen North Road, Shenzhen, 518020, China.
Xi WangThe First Affiliated Hospital (Shenzhen People's Hospital), Southern University of Science and Technology, Shenzhen, 518055, China.
Xiaoni ZhongClinical Medical Research Center, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, No. 1017 Dongmen North Road, Shenzhen, 518020, China.
Dong ZhaoDepartment of Nephrology Center, Department of Liver Transplant Center, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, 518100, Guangdong, China.
Zhipeng ZengClinical Medical Research Center, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, No. 1017 Dongmen North Road, Shenzhen, 518020, China.
Wanxia CaiClinical Medical Research Center, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, No. 1017 Dongmen North Road, Shenzhen, 518020, China.
Jiayi LiuClinical Medical Research Center, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, No. 1017 Dongmen North Road, Shenzhen, 518020, China.
Jianrong HuangDepartment of Nephrology Center, Department of Liver Transplant Center, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, 518100, Guangdong, China. 512370661@qq.com.
Donge TangClinical Medical Research Center, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, No. 1017 Dongmen North Road, Shenzhen, 518020, China. donge66@126.com.
Yong DaiClinical Medical Research Center, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, No. 1017 Dongmen North Road, Shenzhen, 518020, China. daiyong22@aliyun.com.
Jinan University · CNSouthern University of Science and Technology · CNInstitute of Cognitive and Brain Sciences · US

Funding

Guangxi Key Laboratory of Metabolic Diseases Research 20-065-76Shenzhen Key Medical Discipline Construction Fund SZXK059Shenzhen Science and Technology R&D Fund JCYJ20190809165813331The Scientific Research Youth Fund of Shenzhen Third People's Hospital G2021008
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is one of the deadliest cancers and is mainly developed from chronic liver diseases such as hepatitis-B infection-associated liver cirrhosis (LC). The progression from LC to HCC makes the detection of diagnostic biomarkers to be challenging. Hence, there have been constant efforts to improve on identifying the critical and predictive changes accompanying the disease progression.

methodsIn this study, we looked to using the mass spectrometry mediated spatial metabolomics technique to simultaneous examine hundreds of metabolites in an untargeted fashion. Additionally, metabolic profiles were compared between six subregions within the HCC tissue to collect spatial information.

resultsThrough those metabolites, altered metabolic pathways in LC and HCC were identified. Specifically, the amino acid metabolisms and the glycerophospholipid metabolisms experienced the most changes. Many of the altered metabolites and metabolic pathways were able to be connected through the urea cycle.

conclusionsThe identification of the key metabolites and pathways can expand our knowledge on HCC metabolic reprogramming and help us exam potential biomarkers for earlier detection of the malignant disease progression.

Indexed as

Amino acid metabolismDisease progressionHepatocellular carcinomaLiver cirrhosisSpatial metabolomics

Identifiers

PMID36419080
PMCPMC9686114
OpenAlexW4309883493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.